BioAtla, Inc. Files 8-K Report

Ticker: BCAB · Form: 8-K · Filed: Mar 27, 2025 · CIK: 1826892

Sentiment: neutral

Topics: 8-K, financial-reporting

TL;DR

BioAtla filed an 8-K on 3/27/25. Check it for financial updates.

AI Summary

On March 27, 2025, BioAtla, Inc. filed an 8-K report detailing financial results and other material information. The filing indicates the company's principal executive offices are located at 11085 Torreyana Road, San Diego, California, 92121. This report is filed under the Securities Exchange Act of 1934.

Why It Matters

This 8-K filing provides an official update on BioAtla, Inc.'s financial condition and operational status, which is crucial for investors and stakeholders to assess the company's performance and future prospects.

Risk Assessment

Risk Level: low — This filing is a routine 8-K report and does not appear to contain any immediate negative news or significant changes that would elevate the risk level.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for BioAtla, Inc.?

The primary purpose of this 8-K filing is to report current information about BioAtla, Inc.'s results of operations, financial condition, and other material events as required by the Securities Exchange Act of 1934.

When was this 8-K report filed by BioAtla, Inc.?

This 8-K report was filed on March 27, 2025.

What is the principal executive office address for BioAtla, Inc.?

The principal executive office address for BioAtla, Inc. is 11085 Torreyana Road, San Diego, California, 92121.

Under which section of the Securities Exchange Act is this report filed?

This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

What is BioAtla, Inc.'s SIC code?

BioAtla, Inc.'s Standard Industrial Classification (SIC) code is 2836, which corresponds to Biological Products (No Diagnostic Substances).

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on March 27, 2025 regarding BioAtla, Inc. (BCAB).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing